- Home
- UNCY vs EMIS Comparison
UNCY vs EMIS Comparison
Compare UNCY & EMIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$7.07
N/A
Current Price
$10.05
Company Overview
Basic Information| Metric | UNCY | EMIS |
|---|---|---|
| Founded | 2016 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8M | 157.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | UNCY | EMIS |
|---|---|---|
| Price | $7.07 | $10.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $44.50 | N/A |
| AVG Volume (30 Days) | ★ 473.7K | 9.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $9.91 |
| 52 Week High | $7.57 | $10.09 |
Technical Indicators
Market Signals| Indicator | UNCY | EMIS |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 55.13 |
| Support Level | $5.90 | $10.03 |
| Resistance Level | $7.43 | $10.09 |
| Average True Range (ATR) | 0.34 | 0.01 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 88.71 | 50.00 |
Price Performance
Historical Comparison UNCY
EMIS
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About EMIS Emmis Acquisition Corp. Class A Ordinary Shares
Emmis Acquisition Corp is a blank check company.